Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.64 |
| ▸ | GSK3A | P49840 | 3/20 | 0.64 |
| ▸ | GSK3B | P49841 | 3/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146412 | 0.80 | MGLL (1.00) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL3384174 | 0.78 | GSK3A (1.00) | MGLLFAAHGSK3AGSK3BCMA1 | |
| SCHEMBL13243308 | 0.76 | MGLL (0.72) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL6159600 | 0.75 | MGLL (0.69) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL8950019 | 0.74 | MGLL (0.86) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL21215698 | 0.74 | MGLL (0.86) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL7218376 | 0.72 | MGLL (0.82) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL13520165 | 0.72 | HPGD (0.40) | CMA1HTTALDH1A1MAPT | |
| SCHEMBL32665550 | 0.72 | MGLL (0.60) | MGLLFAAHGSK3AGSK3BPTGS1 | |
| SCHEMBL9610843 | 0.71 | MGLL (1.00) | MGLLFAAHGSK3AGSK3BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5475021-A | Administering N-substituted succinimides | VANDERBILT UNIVERSITY (US) | 1995-12-12 | — | — | US | claimed |
| WO-1995015163-A1 | NOVEL COMPOUNDS FOR INHIBITION OF CYCLOOXYGENASE ACTIVITY | VANDERBILT UNIVERSITY (US) | 1995-06-08 | — | — | WO | claimed |
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9067929-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-8586600-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-5475021-A | Administering N-substituted succinimides | VANDERBILT UNIVERSITY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995015163-A1 | NOVEL COMPOUNDS FOR INHIBITION OF CYCLOOXYGENASE ACTIVITY | VANDERBILT UNIVERSITY (US) | 1995-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252019-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | MGLL 2503/4885FAAH 957/4885GSK3A 1561/4885 |
| US-20140073661-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | MGLL 2503/4885FAAH 957/4885GSK3A 1561/4885 |
| US-20120238593-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | MGLL 2503/4885FAAH 957/4885GSK3A 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.